NF-κB deregulation in Hodgkin lymphoma

MA Weniger, R Küppers - Seminars in cancer biology, 2016 - Elsevier
MA Weniger, R Küppers
Seminars in cancer biology, 2016Elsevier
Abstract Hodgkin and Reed/Sternberg (HRS) cells in classical Hodgkin lymphoma (HL)
show constitutive activity of both the canonical and non-canonical NF-κB signaling
pathways. The central pathogenetic role of this activity is indicated from studies with HL cell
lines, which undergo apoptosis upon NF-κB inhibition. Multiple factors contribute to the
strong NF-κB activity of HRS cells. This includes interaction with other cells in the lymphoma
microenvironment through CD30, CD40, BCMA and other receptors, but also recurrent …
Abstract
Hodgkin and Reed/Sternberg (HRS) cells in classical Hodgkin lymphoma (HL) show constitutive activity of both the canonical and non-canonical NF-κB signaling pathways. The central pathogenetic role of this activity is indicated from studies with HL cell lines, which undergo apoptosis upon NF-κB inhibition. Multiple factors contribute to the strong NF-κB activity of HRS cells. This includes interaction with other cells in the lymphoma microenvironment through CD30, CD40, BCMA and other receptors, but also recurrent somatic genetic lesions in various factors of the NF-κB pathway, including destructive mutations in negative regulators of NF-κB signaling (e.g. TNFAIP3, NFKBIA), and copy number gains of genes encoding positive regulators (e.g. REL, MAP3K14). In Epstein-Barr virus-positive cases of classical HL, the virus-encoded latent membrane protein 1 causes NF-κB activation by mimicking an active CD40 receptor. NF-κB activity is also seen in the tumor cells of the rare nodular lymphocyte predominant form of HL, but the causes for this activity are largely unclear.
Elsevier